Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaCore

Full company profile

uuid000pcqo

Namestring
PharmaCore
Websiteurl
pharmacore.com
Company typeenum
Private
Founded yearint
1981
Descriptiontext

PharmaCore is described in firmographic inputs as a United States-based, for-profit company founded in 1999 that offered custom synthesis, R&D, analytical testing, and related chemistry services to biotechnology and pharmaceutical clients, headquartered in High Point and operating at a headcount range of 101–250 employees. The stated business model is a B2B chemistry services model, supplying custom synthesis and analytical capabilities to biotech and pharma customers; however, no pricing model, named customers, product portfolio, certifications (e.g., cGMP), or technical platform architecture are disclosed in the available source material. The only first-party digital surface — pharmacore.com — does not corroborate an operating chemistry services business. Instead, the website displays a domain listing with a 'Buy now' price of $100,000, an Escrow.com redirect for transaction processing, and a 'Made with ❤️ by Name.si' attribution, indicating the domain itself is the marketable asset. All revenue, headcount, customer, and operational signals that would substantiate an active CDMO/analytical chemistry business are absent; the source notes explicitly flag that the $100,000 figure is a domain sale price, not product pricing or revenue. The net evidence base supports characterizing PharmaCore as either a dormant wind-down of the originally described chemistry services firm, or a defunct entity whose only remaining transactable asset is its domain name; the firmographic description should be treated as legacy/stale pending corroboration.

Short descriptiontext

PharmaCore is listed in firmographic data as a US-based chemistry services provider (founded 1999, High Point, NC) offering custom synthesis, R&D, and analytical testing to biotech and pharmaceutical clients; however, its only observable web presence is a $100,000 domain-name sale listing, with no current operating content.

Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEast Rutherford, United States
HQ citystring
East Rutherford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
custom chemical synthesis, pharmaceutical R&D services, analytical chemistry testing, contract research chemistry, biotechnology chemistry services
Industry2 codes
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAF
Small-Molecule Analytical Development & Method Validation (CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
Product category
Contract Chemistry Services
Social media profiles2 records
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmaCore is described as a chemistry services company that offers custom synthesis, research and development support, and analytical testing for biotechnology and pharmaceutical clients. The company's website (pharmacore.com) currently presents only a domain-for-sale listing at $100,000 with transaction processing routed through Escrow.com, with no active service offerings, product catalog, or operating storefront evidenced on the web property.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PharmaCore offers a single product for sale — the pharmacore.com domain. The domain is listed at $100,000 and transactions are facilitated through Escrow.com escrow services. No additional modules, add-ons, or related product offerings are described in the available source material.

Product and service1 record
1Pharmacore.com Domain Listing
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaCore

Contract Chemistry Servicespharmacore.com

PharmaCore is listed in firmographic data as a US-based chemistry services provider (founded 1999, High Point, NC) offering custom synthesis, R&D, and analytical testing to biotech and pharmaceutical clients; however, its only observable web presence is a $100,000 domain-name sale listing, with no current operating content.

What PharmaCore does

PharmaCore is described in firmographic inputs as a United States-based, for-profit company founded in 1999 that offered custom synthesis, R&D, analytical testing, and related chemistry services to biotechnology and pharmaceutical clients, headquartered in High Point and operating at a headcount range of 101–250 employees. The stated business model is a B2B chemistry services model, supplying custom synthesis and analytical capabilities to biotech and pharma customers; however, no pricing model, named customers, product portfolio, certifications (e.g., cGMP), or technical platform architecture are disclosed in the available source material. The only first-party digital surface — pharmacore.com — does not corroborate an operating chemistry services business. Instead, the website displays a domain listing with a 'Buy now' price of $100,000, an Escrow.com redirect for transaction processing, and a 'Made with ❤️ by Name.si' attribution, indicating the domain itself is the marketable asset. All revenue, headcount, customer, and operational signals that would substantiate an active CDMO/analytical chemistry business are absent; the source notes explicitly flag that the $100,000 figure is a domain sale price, not product pricing or revenue. The net evidence base supports characterizing PharmaCore as either a dormant wind-down of the originally described chemistry services firm, or a defunct entity whose only remaining transactable asset is its domain name; the firmographic description should be treated as legacy/stale pending corroboration.

PharmaCore firmographics

Firmographics
Name
PharmaCore
Website
https://pharmacore.com
Company type
Private
Founded year
1981
Headcount range
51–100 employees
Short description
PharmaCore is listed in firmographic data as a US-based chemistry services provider (founded 1999, High Point, NC) offering custom synthesis, R&D, and analytical testing to biotech and pharmaceutical clients; however, its only observable web presence is a $100,000 domain-name sale listing, with no current operating content.
Ownership category
akta.pro rank

PharmaCore industry classification

Industry
Product category
Contract Chemistry Services
akta.pro industry
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAF
Small-Molecule Analytical Development & Method Validation (CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Custom chemical synthesis
  • Pharmaceutical R&D services
  • Analytical chemistry testing
  • Contract research chemistry
  • Biotechnology chemistry services

Where PharmaCore is headquartered

Location

Headquarters

HQ city
East Rutherford
HQ country
United States
HQ region
North America

Markets served

PharmaCore business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Distribution channels1 record

PharmaCore product offering

Product offering

Core offering

PharmaCore is described as a chemistry services company that offers custom synthesis, research and development support, and analytical testing for biotechnology and pharmaceutical clients. The company's website (pharmacore.com) currently presents only a domain-for-sale listing at $100,000 with transaction processing routed through Escrow.com, with no active service offerings, product catalog, or operating storefront evidenced on the web property.

Product overview

PharmaCore offers a single product for sale — the pharmacore.com domain. The domain is listed at $100,000 and transactions are facilitated through Escrow.com escrow services. No additional modules, add-ons, or related product offerings are described in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmacore.com Domain Listing

Companies that use PharmaCore

Customer profile

Ideal customer profiles1 record

PharmaCore technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PharmaCore partnerships and signals

Strategic signal

Recent moves2 records

PharmaCore competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

PharmaCore social profiles

Digital presence

PharmaCore financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaCore leadership team

Management profile

Number of profiles

PharmaCore funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaCore M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaCore

What does PharmaCore do?

PharmaCore is described as a chemistry services company that offers custom synthesis, research and development support, and analytical testing for biotechnology and pharmaceutical clients. The company's website (pharmacore.com) currently presents only a domain-for-sale listing at $100,000 with transaction processing routed through Escrow.com, with no active service offerings, product catalog, or operating storefront evidenced on the web property.

When was PharmaCore founded?

PharmaCore was founded in 1981. It employs 51 to 100 people.

Where is PharmaCore based?

PharmaCore is headquartered in East Rutherford, United States, in the North America region.

Does PharmaCore have an API?

No public API is recorded for PharmaCore.

What industry is PharmaCore in?

PharmaCore's product category is Contract Chemistry Services. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services, with a secondary code of HLAGAHAF, Small-Molecule Analytical Development & Method Validation (CMC).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireResearch Reports Coverage on Biotech Stocks -- Radius Health, Vitae Pharma, Global Blood Therapeutics, and CambrexOn October 13, 2016, Charles Schwab assigned the biotech sector a "Market Perform" rating, citing continued healthcare service demand and strong financials, while Stock-Callers.com initiated research coverage on four biotech equities. Vitae Pharmaceuticals announced the expiration of the Hart-Scott Rodino waiting period for Allergan's pending acquisition, with closure expected in Q4 2016, while Cambrex completed its acquisition of PharmaCore, Inc. to enhance early clinical phase product development capabilities. Global Blood Therapeutics reached agreement with the U.S. FDA on the design of its pivotal Phase 3 HOPE Study for GBT440 in sickle cell disease, with patient screening anticipated by December 2016 and top-line data expected in H1 2019.GlobeNewswireCambrex Completes Acquisition of PharmaCore, Inc.Cambrex completed its acquisition of PharmaCore, a North Carolina-based small molecule API developer, renaming it Cambrex High Point, Inc. The deal, announced September 26, 2016, enhances Cambrex's capabilities for early clinical phase product development. The company expects benefits to earnings per share and other potential benefits.GlobeNewswireCambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API CapabilitiesCambrex agreed to acquire PharmaCore Inc. for approximately $25 million to expand its clinical-stage API capabilities. PharmaCore generates $15-17 million in annual revenue and over $2 million in EBITDA. The deal is expected to be neutral on EPS in 2016 and accretive in 2017.